Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > SVA Fair value is $2.08 according to MS

<< Previous

Bullboard Posts

Next >>

Comment by Redbaron2211on Apr 16, 2021 12:12pm

108 Views

Post# 33011323

RE:RE:RE:SVA Fair value is $2.08 according to MS

Look at the MD&A its clear other indications are going to clinic and this would be reflective of higher spending. I was expecting Hemophilia first but given the focus around thyroid and Dr. Wiseman added to Sernova’s Scientific Advisory Board likely to see thyroid first. If you follow the breadcrumbs its obvious Philip has been a bit busier then some are giving him credit for.
User image